Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections - Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 9, 9, 34, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 7 molecules, respectively.

Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Overview
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Companies Involved in Therapeutics Development
Acurx Pharmaceuticals Inc
Adiso Therapeutics Inc
Affinivax Inc
Appili Therapeutics Inc
Ascendo Biotechnology Inc
Biomica
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Cambimune Ltd
Chain Biotechnology Ltd
Crestone Inc
CSA Biotechnologies LLC
Daiichi Sankyo Co Ltd
Deinove SAS
Destiny Pharma Plc
Enterobiotix Ltd
Facile Therapeutics Inc
Finch Therapeutics Group Inc
First Wave BioPharma Inc
Fzata Inc
Gateway Pharmaceutical LLC
GSK plc
Idorsia Pharmaceutical Ltd
Immune Biosolutions Inc
ImmuneBiotech AB
ImmuniMed Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
KamTek Inc
Kowa Co Ltd
Lumen Bioscience Inc
Malachite Innovations Inc
Mapp Biopharmaceutical Inc
Matrivax Research & Development Corp
MGB Biopharma Ltd
Microbiotica Ltd
Micropharm Ltd
Mikrobiomik Healthcare Company SL
MV BioTherapeutics SA
MyBiotics Pharma Ltd
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Nubiyota LLC
Oragenics Inc
Ostrich Pharma USA Inc
PanTheryx Inc
Pfizer Inc
Proxi Biotech IVS
Pylum Biosciences Inc
Q2 Pharma Ltd
QureTech Bio AB
Rebiotix Inc
Rebus Holdings Inc
Recursion Pharmaceuticals Inc
Sano Chemicals Inc
Scioto Biosciences Inc
Secretory IgA Inc
Seres Therapeutics Inc
Servatus Ltd
Summit Therapeutics Inc
Symbiotic Health Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Vedanta Biosciences Inc
Versatope Therapeutics Inc
Vifor Pharma Ltd
XBiotech Inc
Zhiyi Pharmaceuticals Inc
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drug Profiles
AB-2367 – Drug Profile
ADS-024 – Drug Profile
Antibodies for Clostridium Difficile Infections – Drug Profile
Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections – Drug Profile
AvR-2V10 – Drug Profile
AZX-1101 – Drug Profile
Biologic 1 for Clostridium Difficile Infections – Drug Profile
Biologic for Clostridium Difficile Infections – Drug Profile
Biologics for Clostridium Difficile Infections – Drug Profile
BMC-201 – Drug Profile
CHN-2 – Drug Profile
clofazimine – Drug Profile
Clostridium difficile vaccine – Drug Profile
CP-101 – Drug Profile
CRS-3123 – Drug Profile
CSA-13 – Drug Profile
DNV-3681 – Drug Profile
DNV-3837 – Drug Profile
Drug for Clostridium difficile Infections – Drug Profile
Drugs for Clostridioides Difficile Infections – Drug Profile
DS-11960558 – Drug Profile
ebselen – Drug Profile
F-19 – Drug Profile
FZ-001 – Drug Profile
FZ-002 – Drug Profile
FZ-003 – Drug Profile
FZ-020 – Drug Profile
GmPcide-1 – Drug Profile
GSK-2904545A – Drug Profile
HSGN-218 – Drug Profile
IB-002 – Drug Profile
ibezapolstat – Drug Profile
IM-01 – Drug Profile
IMM-529 – Drug Profile
INS-5010 – Drug Profile
LMNCdiff-01 – Drug Profile
MBK-001 – Drug Profile
MBXSD-201 – Drug Profile
MBXSD-202 – Drug Profile
MET-2 – Drug Profile
metronidazole – Drug Profile
MGBBP-3 – Drug Profile
Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections – Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections – Drug Profile
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections – Drug Profile
Monoclonal Antibody to Inhibit Plasminogen for Clostridioides Difficile Infections – Drug Profile
MUT-001 – Drug Profile
MV-001 – Drug Profile
MVX-02 – Drug Profile
NP-432 – Drug Profile
OG-253 – Drug Profile
OraCAb – Drug Profile
Oral Immunotherapy – Drug Profile
P-100031 – Drug Profile
PBCD-01 – Drug Profile
PF-06425090 – Drug Profile
PolyCAb – Drug Profile
Polymers for Clostridium difficile Infections and Candidiasis – Drug Profile
PTX-300 – Drug Profile
Ramizol – Drug Profile
Ramizol SR – Drug Profile
RBX-2660 – Drug Profile
RBX-7455 – Drug Profile
REC-163964 – Drug Profile
REC-164014 – Drug Profile
ribaxamase – Drug Profile
ridinilazole – Drug Profile
SB-121 – Drug Profile
SER-109 – Drug Profile
SK-08 – Drug Profile
Small Molecule for Clostridium Difficile Infections – Drug Profile
Small Molecules for Clostridium Difficile Infections – Drug Profile
Small Molecules to Antagonize ADORA2A and ADORA2B for Clostridium difficile Infections – Drug Profile
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections – Drug Profile
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases – Drug Profile
SQ-641 – Drug Profile
SU-3327 – Drug Profile
SYN-006 – Drug Profile
SYN-007 – Drug Profile
TAK-039 – Drug Profile
TNP-2198 – Drug Profile
VB-100 – Drug Profile
VE-303 – Drug Profile
VP-20621 – Drug Profile
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Product Development Milestones
Featured News & Press Releases
Jul 07, 2022: Immuron receives European Patent Notification on drug composition to treat clostridioides difficile associated disease
Jun 28, 2022: Vedanta unveils state-of-the-art manufacturing facility to provide clinical and commercial supply of oral therapies based on defined bacterial consortia
Jun 07, 2022: Seres Therapeutics announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection
May 24, 2022: Ferring presents new analyses of efficacy, safety and microbiome composition data at DDW 2022 for RBX2660 its investigational microbiota-based live biotherapeutic
May 22, 2022: Seres Therapeutics presents phase III results of SER-109 for recurrent C. Difficile infection at the Digestive Disease Week (DDW) Annual Meeting
May 19, 2022: Adiso Therapeutics' ADS024 selected for oral presentation at 2022 Digestive Disease Week Annual Meeting
May 12, 2022: Destiny Pharma: World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
May 10, 2022: Seres Therapeutics to present data on investigational microbiome therapeutic SER-109 for recurrent C. difficile infection at the Digestive Disease Week (DDW) Annual Meeting
Apr 28, 2022: Finch Therapeutics announces removal of FDA clinical hold on CP101 IND
Apr 21, 2022: Adiso Therapeutics announces completion of enrollment in a phase 1b study of ADS024 for the Prevention of C. difficile Recurrence
Apr 18, 2022: Lumen Bioscience announces clinical advancement of LMN-201 for C. difficile Infection
Apr 13, 2022: Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in Cell Host & Microbe nd highlights planned presentations of phase 2 VE303 results
Apr 07, 2022: The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada
Mar 01, 2022: Finch Therapeutics provides an update on its phase 3 trial of CP101 in Recurrent C. difficile Infection
Mar 01, 2022: Phase 3 CLOVER Trial for Pfizer’s investigational Clostridioides Difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Universities/Institutes, 2022
Table 7: Products under Development by Companies, 2022
Table 8: Products under Development by Companies, 2022 (Contd..1)
Table 9: Products under Development by Companies, 2022 (Contd..2)
Table 10: Products under Development by Companies, 2022 (Contd..3)
Table 11: Products under Development by Companies, 2022 (Contd..4)
Table 12: Products under Development by Universities/Institutes, 2022
Table 13: Number of Products by Stage and Target, 2022
Table 14: Number of Products by Stage and Mechanism of Action, 2022
Table 15: Number of Products by Stage and Route of Administration, 2022
Table 16: Number of Products by Stage and Molecule Type, 2022
Table 17: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Acurx Pharmaceuticals Inc, 2022
Table 18: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Adiso Therapeutics Inc, 2022
Table 19: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Affinivax Inc, 2022
Table 20: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Appili Therapeutics Inc, 2022
Table 21: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Ascendo Biotechnology Inc, 2022
Table 22: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Biomica, 2022
Table 23: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Botanix Pharmaceuticals Ltd, 2022
Table 24: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2022
Table 25: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Cambimune Ltd, 2022
Table 26: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Chain Biotechnology Ltd, 2022
Table 27: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Crestone Inc, 2022
Table 28: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by CSA Biotechnologies LLC, 2022
Table 29: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 30: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Deinove SAS, 2022
Table 31: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Destiny Pharma Plc, 2022
Table 32: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Enterobiotix Ltd, 2022
Table 33: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Facile Therapeutics Inc, 2022
Table 34: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Finch Therapeutics Group Inc, 2022
Table 35: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by First Wave BioPharma Inc, 2022
Table 36: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Fzata Inc, 2022
Table 37: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Gateway Pharmaceutical LLC, 2022
Table 38: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by GSK plc, 2022
Table 39: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Idorsia Pharmaceutical Ltd, 2022
Table 40: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Immune Biosolutions Inc, 2022
Table 41: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmuneBiotech AB, 2022
Table 42: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmuniMed Inc, 2022
Table 43: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmunoBiology Ltd, 2022
Table 44: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Immuron Ltd, 2022
Table 45: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Inovio Pharmaceuticals Inc, 2022
Table 46: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Integrated BioTherapeutics Inc, 2022
Table 47: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by KamTek Inc, 2022
Table 48: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Kowa Co Ltd, 2022
Table 49: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Lumen Bioscience Inc, 2022
Table 50: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Malachite Innovations Inc, 2022
Table 51: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Mapp Biopharmaceutical Inc, 2022
Table 52: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Matrivax Research & Development Corp, 2022
Table 53: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MGB Biopharma Ltd, 2022
Table 54: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Microbiotica Ltd, 2022
Table 55: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Micropharm Ltd, 2022
Table 56: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Mikrobiomik Healthcare Company SL, 2022
Table 57: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MV BioTherapeutics SA, 2022
Table 58: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MyBiotics Pharma Ltd, 2022
Table 59: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Novabiotics Ltd, 2022
Table 60: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
Table 61: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Nubiyota LLC, 2022
Table 62: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Oragenics Inc, 2022
Table 63: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Ostrich Pharma USA Inc, 2022
Table 64: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by PanTheryx Inc, 2022
Table 65: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Pfizer Inc, 2022
Table 66: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Proxi Biotech IVS, 2022
Table 67: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Pylum Biosciences Inc, 2022
Table 68: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Q2 Pharma Ltd, 2022
Table 69: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by QureTech Bio AB, 2022
Table 70: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Rebiotix Inc, 2022
Table 71: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Rebus Holdings Inc, 2022
Table 72: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Recursion Pharmaceuticals Inc, 2022
Table 73: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Sano Chemicals Inc, 2022
Table 74: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Scioto Biosciences Inc, 2022
Table 75: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Secretory IgA Inc, 2022
Table 76: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Seres Therapeutics Inc, 2022
Table 77: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Servatus Ltd, 2022
Table 78: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Summit Therapeutics Inc, 2022
Table 79: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Symbiotic Health Inc, 2022
Table 80: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Synthetic Biologics Inc, 2022
Table 81: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 82: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by TenNor Therapeutics Ltd, 2022
Table 83: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Vedanta Biosciences Inc, 2022
Table 84: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Versatope Therapeutics Inc, 2022
Table 85: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Vifor Pharma Ltd, 2022
Table 86: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by XBiotech Inc, 2022
Table 87: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Zhiyi Pharmaceuticals Inc, 2022
Table 88: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2022
Table 89: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2022 (Contd..1)
Table 90: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2022 (Contd..2)
Table 91: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2022 (Contd..3)
Table 92: Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings